|
|
PrognostiX, a privately-held spin out of the Cleveland Clinic Foundation, is focused on cardiovascular disease management. The company's CardioMPO™ test, which aids in the diagnosis of near-term heart attack and cardiac death risk is the first FDA-cleared diagnostic of its kind. PrognostiX's proprietary product pipeline includes valuable, high-margin cardiovascular and inflammatory biomarkers licensed to it exclusively by the Cleveland Clinic, the world's most respected cardiovascular center. The company operates a CLIA-certified and CAP-accredited specialty reference laboratory, enabling it to bring promising new cardiovascular biomarkers to market.
July 6, 2009: Advance Laboratory Article Feature: Arterial Inflammation Biomarkers
May 21, 2009: PrognostiX Receives CAP Laboratory Reaccreditation, Expands Test Menu
Jan. 12, 2009: PrognostiX to Present at OneMedForum 2009
Jan. 6, 2009: PrognostiX Awarded Grant to Support Product Development, Commercialization
Nov. 4, 2008: Inverness Medical Innovations, PrognostiX Sign Distribution Agreement for CardioMPO™ Test
Oct. 16, 2008: PrognostiX Appoints Diagnostics Industry Veteran Orville President and Chief Executive
April 24, 2007: PrognostiX Secures Exclusive License to Important Cardiac Biomarker
|